Bovie Medical Announces Market Release of Canady APC Probes; FDA Submission of MEG Laparoscopic Instrument Line

Business Wire, June 3, 2008

MELVILLE, N.Y. -- Bovie Medical Corporation (the "Company") (Amex: BVX), a manufacturer and marketer of electrosurgical products, today announced it recently launched the marketing of the Canady Argon Plasma Coagulation (APC) probes at the Digestive Disease Week (DDW) convention held in San Diego, CA. The DDW is the largest convention for gastroenterologists in the United States. Under a manufacturing and distribution agreement with Canady Technology signed last year, Bovie has been developing argon plasma probes for Canady Technology. The agreement allows Bovie to manufacture and distribute these Canady branded products through their GI distributors. The new probes incorporate several competitive advantages including price, a tip that prevents melting during prolonged use as well as several lengths and sizes in order to adapt to various procedures.

Bovie also announced it has submitted to the Food & Drug Administration (FDA) a 510(k) application for its Modular Ergonomic Instrument line (MEG line). The Company recently announced a CE Mark with the European Union (EU) allowing the MEG line to be marketed throughout the EU.

Management's focus over the next several months will be to introduce new products into the marketplace; thus, expanding the Company's future revenue sources.

This document may contain some forward looking statements, particularly regarding operational prospects in 2008 and beyond, which involve a number of risks and uncertainties that could cause actual results to differ materially. These risks are listed from time to time in the Company's SEC filings. www.boviemedical.com.